InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges
InMode (NASDAQ: INMD) has secured a significant legal victory against counterfeit sellers on DHGate platform.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
InMode (NASDAQ: INMD) has secured a significant legal victory against counterfeit sellers on DHGate platform. The US District Court for the Central District of California has granted InMode a permanent injunction and damages against defendants selling counterfeit Morpheus8 radio frequency microneedling devices and needle cartridges. The court ruling includes freezing the defendants' assets and halting their product listings.
The decision favors InMode on all claims including trademark infringement, false designation of origin, and California unfair competition. To combat counterfeiting, InMode has launched a Verified Provider Program for Morpheus8, enabling certified clinics to demonstrate their authenticity. Patients can verify authorized providers through InMode's Find a Provider tool at www.inmodemd.com.
Positive
- None.
Negative
- Presence of counterfeit products in the market indicates potential revenue loss and brand reputation risks
Details
News Market Reaction – INMD
The recorded move for INMD in the trading session of this news was +0.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Court's decision aims to protect safety and uphold InMode's trademark rights. The injunction includes freezing the assets and halting the listings of the sellers involved in the counterfeit trade. The ruling favors InMode on all claims (trademark infringement, false designation of origin, and
"InMode maintains a zero-tolerance policy towards fraudulent business practices including counterfeit goods and for any platforms or sellers who are using, selling, or distributing false products," says Moshe Mizrahy, CEO of InMode. "We are committed to public safety and will continue to protect consumers from potential harm caused by unauthorized Morpheus8 devices."
InMode has established a Verified Provider Program for Morpheus8, allowing certified clinics to showcase their authenticity and confirm they use genuine Morpheus8 technology. This initiative helps patients identify safe, authorized providers committed to delivering trusted InMode results.
Patients in
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Press Contact:
Behrman Cesa Communications
inmode@behrmancesa.com
Investor Contact:
MS-IR LLC
Miri Segal – Scharia
ir@inmodemd.com
Tel: 917-607-8654
Logo - https://mma.prnewswire.com/media/1064477/5298285/InMode_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/inmode-granted-injunction-against-counterfeit-sales-of-morpheus8-radio-frequency-microneedling-devices-and-needle-cartridges-302446235.html
SOURCE InMode Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.